Off-the-Shelf immune cells take on Hard-to-Treat lymphomas
NCT ID NCT04848064
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial is testing a combination of donor natural killer (NK) cells and the drug mogamulizumab in 12 patients with relapsed or refractory cutaneous T-cell lymphoma or adult T-cell leukemia/lymphoma. The NK cells are grown in the lab and given 'off the shelf' to boost the immune system's ability to attack cancer, while mogamulizumab helps flag cancer cells for destruction. The main goal is to find the safest dose and see if the combination can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
natural killer (NK) cells from healthy donors, combined with mogamulizumab (a monoclonal antibody)
What this could lead to
If it works, this could point toward a new treatment option for patients with T-cell lymphomas that have stopped responding to standard therapies.
What could go wrong
This is a very early phase I trial with only 12 participants, so it is primarily testing safety and dosing. The combination may not work or could cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact